]>
IRCT20200421047155N1 IRCT 2020-04-25 Ardabil University of Medical Sciences Efficacy of tenofovir in covid-19 Therapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19 2020-04-29 anticipated 86 Complete https://irct.ir/trial/47387 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Each patient will be randomly allocated into one of the cases or study groups by using the "research randomizer" website facility, Blinding description: All patients will remain unaware of in which group (study or control) they are. 3 COVID-19. Intervention 1: Intervention group: PO Hydroxychloroquine 200 mg and PO tenofovir 300 mg once a day for 7 days. Intervention 2: Control group: PO Hydroxychloroquine 200 mg once a day for 7 days. Yes - There is a plan to make this available What will be shared: All of the participants' data reported in the article relative to this trial after deidentification When: Immediately after publication regarding the publisher's policy To whom: Researchers who provide a methodologically sound proposal. Conditions: Any purpose Where to obtain: Shahram Habibzadeh shahramhabibzadeh@gmail.com Sina Parsay sinaparsa91@gmail.com How to obtain: Proposals should be directed to one of the above-mentioned email addresses. Requestors also will need to sign a data access agreement. Comments:
public Shahram Habibzadeh
Ardabil
Ardabil Iran (Islamic Republic of) 5618985991 +98 45 3325 1401 shahramhabibzadeh@gmail.com Ardabil University of Medical Sciences scientific Shahram Habibzadeh
Department of infectious disease, Imam Khomeini Hospital, Ataii Ave.
Ardabil Iran (Islamic Republic of) 5618985991 +98 45 3325 1401 shahramhabibzadeh@gmail.com Ardabil University of Medical Sciences Iran (Islamic Republic of) Patients with COVID-19 pulmonary infection Established diagnosis of COVID-19 with RTPCR Patients older than 18 years 18 years 80 years Both Reinfection with COVID-19 Pregnancy Patients with immunodeficiency Individuals who are reluctant to participate in study Prior history of allergy to used drugs Documented history of any other medical condition for which the patient require to use a certain medication routinely. Creatinin clearance less than 30 mg/min Oxygen Saturation (SpO2) less than 40% ICU patients U07.1 COVID-19, virus identified Treatment - Drugs Treatment - Drugs Intervention group: PO Hydroxychloroquine 200 mg and PO tenofovir 300 mg once a day for 7 days Control group: PO Hydroxychloroquine 200 mg once a day for 7 days Vital signs. Timepoint: daily. Method of measurement: direct physical examination. Body temperature. Timepoint: daily. Method of measurement: thermometer. White blood cell count. Timepoint: daily. Method of measurement: blood sample analysis. Ardabil University of Medical Sciences Approved 2020-04-18 Ethics committee of Ardabil University of Medical Science Department of infectious disease, Imam Khomeini Hospital, Ataii Ave. Ardabil Ardabil Iran (Islamic Republic of)